-
Signature
-
/s/ Christopher Ogden, as Attorney-in-Fact for Sean A. McCarthy
-
Issuer symbol
-
CTMX
-
Transactions as of
-
06 Nov 2025
-
Net transactions value
-
-$461,906
-
Form type
-
4
-
Filing time
-
10 Nov 2025, 16:05:32 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| McCarthy Sean A. |
CEO, Director |
C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO |
/s/ Christopher Ogden, as Attorney-in-Fact for Sean A. McCarthy |
10 Nov 2025 |
0001654058 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
CTMX |
Class A Common Stock |
Sale |
$461,906 |
-101,793 |
-9.3% |
$4.54 |
987,891 |
06 Nov 2025 |
Direct |
F1, F2, F3 |
| holding |
CTMX |
Class A Common Stock |
|
|
|
|
|
93,158 |
06 Nov 2025 |
See footnote |
F4 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: